Ixchiq HCP

Menu
Menu

Références

  1. Monographie d’IXCHIQMD. 14 janvier 2026.
  2. Données internes sur IXCHIQMD. 2024.
  3. Organisation mondiale de la Santé. Chikungunya. Publié le 14 avril 2025. Disponible au : https://www.who.int/fr/news-room/fact-sheets/detail/chikungunya. Consulté le 26 août 2025.
  4. Craig J, et al. Diagnostic challenges in chikungunya infection. CCDR. 2015;41(1):6–10.
  5. Organisation mondiale de la Santé. Chikungunya – Vue d’ensemble. Disponible au : https://www.who.int/fr/health-topics/chikungunya#tab=tab_1. Consulté le 26 août 2025.
  6. Thiberville SD, et al. Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy. Antivir Res. 2013 ;99(3):345–370.
  7. Sahadeo N, et al. Molecular Characterisation of chikungunya virus infections in Trinidad and comparison of clinical and laboratory features with dengue and other acute febrile cases. PLoS Negl Trop Dis. 2015;9(11):e0004199.
  8. Centre européen de prévention et de contrôle des maladies. 12-month Chikungunya virus disease case notification rate per 100 000 population, February 2025 to January 2026. Disponible au : https://www.ecdc.europa.eu/en/publications-data/12-month-chikungunya-virus-disease-case-notification-rate-100-000-population-9. Consulté le 11 mars 2026. 
  9. Organisation mondiale de la Santé. Chikungunya virus disease- Global situation. Disponible au : https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON581. Consulté le 8 octobre 2025.
  10. Puntasecca CJ, King CH, LaBeaud AD. Measuring the global burden of chikungunya and Zika viruses: A systematic review. PLoS Negl Trop Dis. 2021;15(3):e0009055.
  11. de Souza, et al. Pathophysiology of chikungunya virus infection associated with fatal outcomes. Cell Host Microbe. 2024;32:606–622.
  12. Centre européen de prévention et de contrôle des maladies. Chikungunya worldwide overview. Disponible au : https://www.ecdc.europa.eu/en/chikungunya-monthly. Consulté le 26 août 2025.
  13. Agence de la santé publique du Canada, BCCDC Public Health Laboratory, Alberta Precision Laboratories, Public Health Ontario Laboratory. Can Commun Dis Rep. 2025;51(9):374.
  14. Suhrbier A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat Rev. 2019;15:597–611.
  15. Centers for Disease Control and Prevention. Chikungunya in China. Disponible au : https://wwwnc.cdc.gov/travel/notices/level2/chikungunya-china. Consulté le 26 août 2025.
  16. Centers for Disease Control and Prevention. Chikungunya in Cuba. Disponible au : https://wwwnc.cdc.gov/travel/notices/level2/chikungunya-cuba. Consulté le 3 novembre 2025.
  17. Pan American Health Organization. Chikungunya: analysis by country. Disponible au : https://www.paho.org/en/arbo-portal/chikungunya-data-and-analysis/chikungunya-analysis-country. Consulté le 26 janvier 2026.
  18. Staples JE, Hills S, Powers A. Chapter 4: Chikungunya/ Dans : Nemhauser J, ed. CDC Yellow Book 2026. Centers for Disease Control and Prevention. Disponible au : https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/chikungunya. Consulté le 10 février 2026.
  19. Nemg Simo FB, et al. Chikungunya virus diagnosis: A review of current antigen detection methods. Trop Med Infect Dis. 2023;8(7):365.
  20. Pathak H, et al. Chikungunya arthritis. Clin Med. 2019;19(5):381–385.
  21. Silva L, Dermody T. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737–749.
  22. Paixão ES, et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2018;1123(7):301–316.
  23. Marques CDL, et al. Recommendations of the Brazilian Society of Rheumatology for diagnosis and treatment of Chikungunya fever. Part 1 – Diagnosis and special situations. Rev Bras Reumatol. 2017;57(S2):S421–S437.
  24. Essackjee K, et al. Prevalence of and risk factors for chronic arthralgia and rheumatoid-like polyarthritis more than 2 years after infection with chikungunya virus. Postgrad Med J. 2013;89(1054):440–447.
  25. Organisation mondiale de la Santé. Guidelines on Clinical Management of Chikungunya Fever. Publié en octobre 2008. Disponible au : https://iris.who.int/bitstream/handle/10665/205178/B3234.pdf?sequence=1. Consulté le 25 juillet 2024.
  26. De Roo AM, et al. The global health and economic burden of chikungunya from 2011 to 2020: a model-driven analysis on the impact of an emerging vector-borne disease. BMJ Glob Health. 2024;9:1–11.
  27. Buerger V., et al. Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil. Lancet Infect Dis. 2025.
  28. Schneider M., et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: A double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. 2023;401:2138–2147.
  29. Centers for Disease Control and Prevention. Factors to assess when considering use of chikungunya vaccine. Mis à jour le 15 mai 2024. Disponible au : https://www.cdc.gov/chikungunya/media/pdfs/2024/05/Chikungunya-vaccine-risk-factors-508.pdf. Consulté le 19 juillet 2024.
  30. Boggild AK. et al. Chikungunya in travellers returning to Canada: Surveillance report from CanTravNet surveillance data, 2006 to 2015. J Assoc Med Microbiol Infect Dis Can. 2016;1(3):1–16.
  31. Centers for Disease Control and Prevention. ACIP Recommendations. Mis à jour le 6 mars 2024. Disponible au : https://www.cdc.gov/vaccines/acip/recommendations.html. Consulté le 18 avril 2024.
Valneva Canada Inc. 
Affaires commerciales
3535, boul. Saint-Charles, bureau 600
Kirkland (Montréal), Québec H9H 5B9 Canada
Téléphone : 514-630-6999
Valneva Canada Inc. 
Affaires commerciales
3535, boul. Saint-Charles, bureau 600
Kirkland (Montréal), Québec H9H 5B9 Canada
Téléphone : 514-630-6999